Followers | 3345 |
Posts | 84506 |
Boards Moderated | 7 |
Alias Born | 10/05/2005 |
Saturday, October 10, 2020 10:17:06 AM
Preclinical data demonstrated delayed tumor growth, reduces metastases and anti-tumor immune response
LINK:
https://www.accesswire.com/609786/Inspyr-Therapeutics-Acquires-a-Novel-Immuno-Onoclogy-Precision-Targeting-Platform-for-the-Treatment-of-Cancer
WESTLAKE VILLAGE, CA / ACCESSWIRE / October 9, 2020 / Inspyr Therapeutics, Inc. (OTC/PINK: $NSPX ), announces that it has acquired a novel immuno-oncology delivery technology targeting adenosine receptor antagonists for the treatment of cancer. The technology was previously acquired by Inspyr and then licensed to Ridgeway Therapeutics, Inc. In exchange for: (i) 65,000,000 shares of Common Stock and (ii) 8,000 shares of Series F Convertible Preferred Stock, Inspyr has reacquired all rights previously licenses, as well as improvements thereto made by Ridgeway, and will assume all further preclinical and clinical development relating to RT-AR001 and all other proprietary assets.
About Inspyr Therapeutics. Inc
Inspyr Therapeutics, through the above transaction, is now focused on the development of immune-oncology precision therapies that utilize its proprietary technology targeting delivery of adenosine receptor antagonists as treatments for cancer.
About Ridgeway Therapeutics, Inc
Ridgeway Therapuetics is a private company that has a patented global portfolio of potential first-in-class precision targeting technologies focused for the treatment of cancer. RT-AR001 ‘s intra-tumoral delivery technology has shown more effective drug delivery with an enhanced response rate by targeting the tumor microenvironment.
Cautionary Statement Regarding Forward-Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of Inspyr Therapeutics' technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of Inspyr Therapeutic's proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Investor and Media Contact:
contacts@ridgewaytherapeutics.com
SOURCE: Inspyr Therapeutics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/609786/Inspyr-Therapeutics-Acquires-a-Novel-Immuno-Onoclogy-Precision-Targeting-Platform-for-the-Treatment-of-Cancer
Recent RBSH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:19:43 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:36:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM